This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vernejoul, F. Articles by Buscail, L. Search for Related Content PubMed PubMed Citation Articles by Vernejoul, F. Articles by Buscail, L.

Antitumor Effect of in Vivo Somatostatin Receptor Subtype 2 Gene Transfer in Primary and Metastatic Pancreatic Cancer Models¹

Institut National de la Santé et de la Recherche Médicale U531, Institut Louis Bugnard IFR31, Centre Hospitalier Universitaire Rangueil, 31403 Toulouse Cedex 4, France [F. V., P. F., N. B., D. C., L. P., C. S., L. B.], and Société Cayla, 31403 Toulouse Cedex 4, France [G. T.]

Our previous studies conducted in pancreatic cancer models established in nude mice and hamsters revealed that cloned somatostatin receptor subtype 2 (sst2) gene expression induced both antioncogenic and local antitumor bystander effects in vivo. In the present study, in vivo gene transfer of sst2 was investigated in two transplantable models of primary and metastatic pancreatic carcinoma developed in hamsters. LacZ reporter or mouse sst2 genes were expressed by means of two different delivery agents: an adenoviral vector and a synthetic polycationic carrier [linear polyethylenimine (PEI)]. sst2 was injected into either exponentially growing pancreatic primary tumors or hepatic metastases, and then transgene expression and tumor progression were investigated 5–6 days after gene transfer. Molecular mechanisms involved in the inhibition of tumor growth were also analyzed. Both adenovirus- and PEI-mediated in vivo gene transfer in primary pancreatic tumors induced an increase of ß-galactosidase activity and expression of sst2 transgene nRNA (100% and 86% of tumors for adenovirus and PEI vector, respectively). Adenoviral vector-based sst2 gene transfer resulted in significant reduction of pancreatic tumor growth (P < 0.05). Using PEI vector, both pancreatic primary tumor growth and metastatic tumor growth were also significantly slackened as compared with both LacZ-treated and untreated control groups (P < 0.02). Moreover, the proliferative index decreased significantly (P < 0.005), whereas apoptosis increased (P < 0.005) in tumors transferred with sst2 gene. The increase of apoptosis correlated with an activation of the caspase-3 and poly(ADP-ribose) polymerase pathways. We concluded that in both primary and metastatic pancreatic cancer models, the synthetic gene delivery system can achieve in vivo sst2 gene transfer and results in a significant antitumor effect characterized by an increase of apoptosis and an inhibition of cell proliferation. This new strategy of gene therapy allows the restoration of expression of an antioncogenic molecule and could be promising for the treatment of advanced pancreatic cancer.

This article has been cited by other articles:

				H. Laklai, S. Laval, L. Dumartin, P. Rochaix, M. Hagedorn, A. Bikfalvi, S. Le Guellec, M.-B. Delisle, A. V. Schally, C. Susini, et al. Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer PNAS, October 20, 2009; 106(42): 17769 - 17774. [Abstract] [Full Text] [PDF]

				J. Acunzo, S. Thirion, C. Roche, A. Saveanu, G. Gunz, A. L. Germanetti, B. Couderc, R. Cohen, D. Figarella-Branger, H. Dufour, et al. Somatostatin Receptor sst2 Decreases Cell Viability and Hormonal Hypersecretion and Reverses Octreotide Resistance of Human Pituitary Adenomas Cancer Res., December 15, 2008; 68(24): 10163 - 10170. [Abstract] [Full Text] [PDF]

				F. P. Leu, M. Nandi, and C. Niu The Effect of Transforming Growth Factor {beta} on Human Neuroendocrine Tumor BON Cell Proliferation and Differentiation Is Mediated through Somatostatin Signaling Mol. Cancer Res., June 1, 2008; 6(6): 1029 - 1042. [Abstract] [Full Text] [PDF]

				C Susini and L Buscail Rationale for the use of somatostatin analogs as antitumor agents Ann. Onc., December 1, 2006; 17(12): 1733 - 1742. [Abstract] [Full Text] [PDF]

				H. Lahlou, M. Fanjul, L. Pradayrol, C. Susini, and S. Pyronnet Restoration of Functional Gap Junctions through Internal Ribosome Entry Site-Dependent Synthesis of Endogenous Connexins in Density-Inhibited Cancer Cells Mol. Cell. Biol., May 15, 2005; 25(10): 4034 - 4045. [Abstract] [Full Text] [PDF]

				V. A.S.H. Dalm, L. J. Hofland, C. M. Mooy, M. A. Waaijers, P. M. van Koetsveld, A. W. Langerak, F. T.J. Staal, A.-J. van der Lely, S. W.J. Lamberts, and M. P. van Hagen Somatostatin Receptors in Malignant Lymphomas: Targets for Radiotherapy? J. Nucl. Med., January 1, 2004; 45(1): 8 - 16. [Abstract] [Full Text] [PDF]